血清甲状旁腺素与经皮冠状动脉介入治疗围手术期心肌损伤及预后的相关性研究

陈诗, 吴祖飞, 宗刚军, 等. 血清甲状旁腺素与经皮冠状动脉介入治疗围手术期心肌损伤及预后的相关性研究[J]. 临床心血管病杂志, 2021, 37(4): 332-339. doi: 10.13201/j.issn.1001-1439.2021.04.009
引用本文: 陈诗, 吴祖飞, 宗刚军, 等. 血清甲状旁腺素与经皮冠状动脉介入治疗围手术期心肌损伤及预后的相关性研究[J]. 临床心血管病杂志, 2021, 37(4): 332-339. doi: 10.13201/j.issn.1001-1439.2021.04.009
CHEN Shi, WU Zufei, ZONG Gangjun, et al. Correlation between serum parathyroid hormone and perioperative myocardial injury and prognosis in patients with PCI[J]. J Clin Cardiol, 2021, 37(4): 332-339. doi: 10.13201/j.issn.1001-1439.2021.04.009
Citation: CHEN Shi, WU Zufei, ZONG Gangjun, et al. Correlation between serum parathyroid hormone and perioperative myocardial injury and prognosis in patients with PCI[J]. J Clin Cardiol, 2021, 37(4): 332-339. doi: 10.13201/j.issn.1001-1439.2021.04.009

血清甲状旁腺素与经皮冠状动脉介入治疗围手术期心肌损伤及预后的相关性研究

  • 基金项目:

    江苏省青年医学重点人才基金(No:QNRC2016883)

详细信息
    通讯作者: 吴刚勇,E-mail:wuwangyi520@sina.com
  • 中图分类号: R541.4

Correlation between serum parathyroid hormone and perioperative myocardial injury and prognosis in patients with PCI

More Information
  • 目的:探讨血清甲状旁腺素(PTH)水平对择期经皮冠状动脉介入治疗(PCI)围手术期心肌损伤(PMI)的预测价值及与PCI预后的相关性。方法:纳入199例因心绞痛行择期PCI的患者,根据术后肌钙蛋白I(cTnI)水平分成无损伤组(NC组,cTnI≤0.04 ng/mL,33例)、PCI围手术期心肌损伤组(PMI组,0.04 ng/mL<cTnI≤0.2 ng/mL,85例)、PCI围手术期心肌梗死组(PPMI组,cTnI>0.2 ng/mL,81例),检测PCI手术前后血清PTH水平、术后24 h及48 h内cTnI水平,记录造影结果及手术操作情况,术后规律随访。结果:术前PTH水平在NC组、PMI组、PPMI组中逐渐升高,组间两两比较,差异有统计学意义(P<0.01)。Pearson相关分析显示术前PTH水平与术后cTnI水平显著相关(r=0.449,P<0.001)。受试者工作特征(ROC)曲线分析显示,PTH预测PMI的最佳临界值为43.70 pg/mL,敏感度为69.3%,特异度为75.8%,AUC为0.771。多因素Logistic回归分析显示,术前血清PTH是PCI PMI的独立危险因素(OR=7.42,95%CI:2.56~21.48,P<0.001)。多因素Cox回归分析表明,术前PTH水平(HR=2.07,95%CI:1.11~3.88,P=0.023)和术后发生PMI(HR=2.46,95%CI:1.06~5.73,P=0.037)是PCI患者预后的独立危险因素。结论:术前PTH可预测PMI,并与PCI预后不良独立相关。
  • 加载中
  • [1]

    Writing Group Members,Mozaffarian D,Benjamin EJ,et al.Heart Disease and Stroke Statistics-2016 Update:A Report From the American Heart Association[J].Circulation,2016,133(4):e38-360.

    [2]

    Zeitouni M,Silvain J,Guedeney P,et al.Periprocedural myocardial infarction and injury in elective coronary stenting[J].Eur Heart J,2018,39(13):1100-1109.

    [3]

    Thygesen K,Alpert JS,Jaffe AS,et al.Fourth universal definition of myocardial infarction(2018)[J].J Am Coll Cardiol,2018,72(18):2231-2264.

    [4]

    Soud M,Ho G,Hideo-Kajita A,et al.Periprocedural myocardial injury:Pathophysiology,prognosis,and prevention[J].Cardiovasc Revasc Med,2020,21(8):1041-1052.

    [5]

    Grønhøj MH,Gerke O,Mickley H,et al.Associations between calcium-phosphate metabolism and coronary artery calcification;a cross sectional study of a middle-aged general population[J].Atherosclerosis,2016,251:101-108.

    [6]

    Pascale AV,Finelli R,Giannotti R,et al.Vitamin D,parathyroid hormone and cardiovascular risk:the good,the bad and the ugly[J].J Cardiovasc Med(Hagerstown),2018,19(2):62-66.

    [7]

    DeLuccia R,Cheung M,Ramadoss R,et al.The Endocrine Role of Bone in Cardiometabolic Health[J].Curr Nutr Rep,2019,8(3):281-294.

    [8]

    国家卫生计生委合理用药专家委员会,中国药师协会.冠心病合理用药指南(第2版)[J].中国医学前沿杂志(电子版),2018,10(6):1-130.

    [9]

    Aslanabadi N,Shirzadi HR,Asghari-Soufi H,et al.A pilot randomized trial of pentoxifylline for the reduction of periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention[J].Eur J Clin Pharmacol,2015,71(2):143-149.

    [10]

    Aslanabadi N,Safaie N,Asgharzadeh Y,et al.The randomized clinical trial of coenzyme Q10 for the prevention of periprocedural myocardial injury following elective percutaneous coronary intervention[J].Cardiovasc Ther,2016,34(4):254-260.

    [11]

    Hejazi ME,Modarresi-Ghazani F,Hamishehkar H,et al.The Effect of Treatment of Vitamin D Deficiency on the Level of P-Selectin and hs-CRP in Patients With Thromboembolism:A Pilot Randomized Clinical Trial[J].J Clin Pharmacol,2017,57(1):40-47.

    [12]

    陈伟,伍于斌.经皮冠状动脉介入术心肌损伤预测因子的研究进展[J].医学综述,2018,24(13):2565-2570.

    [13]

    Alsancak Y,Kızıltunç E,Sezenöz B,et al.Association between parathyroid hormone levels and the extensiveness of coronary artery disease[J].Anatol J Cardiol,2016,16(11):839-843.

    [14]

    刘叶红,靳天慧,陈亮,等.血清甲状旁腺激素/HDL-C及LDL-C/HDL-C与冠状动脉病变严重程度的相关性[J].临床心血管病杂志,2020,36(11):985-990.

    [15]

    张雯,孙林,郭子宏.甲状旁腺素与原发性高血压的相关性研究进展[J].中华高血压杂志,2016,24(12):1130-1134.

    [16]

    Lee YH,Kweon SS,Choi JS,et al.Association of serum vitamin D and parathyroid hormone with subclinical atherosclerotic phenotypes:The Dong-gu Study[J].PLoS One,2017,12(10):e0186421.

    [17]

    Pepe J,Cipriani C,Sonato C,et al.Cardiovascular manifestations of primary hyperparathyroidism:a narrative review[J].Eur J Endocrinol,2017,177(6):R297-R308.

    [18]

    Guers JJ,Prisby RD,Edwards DG,et al.Intermittent parathyroid hormone administration attenuates endothelial dysfunction in old rats[J].J Appl Physiol(1985),2017,122(1):76-81.

    [19]

    Datta T,Przyklenk K,Datta NS.Parathyroid Hormone-Related Peptide:A Novel Endocrine Cardioprotective "Conditioning Mimetic"[J].J Cardiovasc Pharmacol Ther,2017,22(6):529-537.

    [20]

    Datta NS,Chukkapalli S,Vengalil N,et al.Parathyroid hormone-related peptide protects cardiomyocytes from oxidative stress-induced cell death:First evidence of a novel endocrine-cardiovascular interaction[J].Biochem Biophys Res Commun,2015,468(1-2):202-207.

  • 加载中
计量
  • 文章访问数:  716
  • PDF下载数:  0
  • 施引文献:  0
出版历程
收稿日期:  2020-08-18
修回日期:  2020-08-28

目录